Stockscreener 앱 받기
45.59
0.93%
-0.43
시간 외 거래:
45.60
0.010
+0.02%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb: Way Too Cheap At 7x P/E (NYSE:BMY) - Seeking Alpha
TIAA Trust National Association Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth - Seeking Alpha
BioNTech Boosts 2025 Outlook as Cancer Drug Alliance with Bristol Myers Squibb Takes Aim at Merck’s Keytruda - Tekedia
Pulmonary Fibrosis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, A - Barchart.com
Balanced Outlook on Bristol-Myers Squibb: Strong Q3 Performance Amid ADEPT-2 Trial Concerns - TipRanks
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership - inkl
Bristol Myers Squibb to present Camzyos efficacy data at AHA scientific sessions - Investing.com
Bristol-Myers Squibb stock rises 7% after clean earnings beat By Investing.com - Investing.com Nigeria
United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceuticals, Astellas Pharma, Baxter, Pfizer, Dr. Reddy's LaboratoriesResearchAndMarkets.com - Business Wire
US Cancer Immunotherapy Forecast and Company Analysis Report 2025-2033 Featuring Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Pfizer, Novartis, Johnson & Johnson, Eli Lily Co, Seattle GeneticsResearchAndMarkets.com - FinancialContent
Bristol-Myers Squibb stock rises 7% after clean earnings beat - Investing.com
Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades' - Benzinga
Verity Asset Management Inc. Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025 - Business Wire
BioNTech raises 2025 revenue guidance after Bristol Myers deal By Investing.com - Investing.com Nigeria
BioNTech raises 2025 revenue guidance after Bristol Myers deal - Investing.com
BioNTech lifts 2025 revenue guidance on BMS partnership payment - Reuters
BioNTech Raises Sales Outlook on Boost from Bristol Payments - Bloomberg.com
Bristol Myers Squibb Co Announces $7 Billion Cash Tender Offers - TradingView
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes - The AI Journal
Published on: 2025-11-02 22:42:16 - newser.com
How Bristol Myers Squibb Company (BRM) stock moves in volatile trading sessionsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Syverson Strege & Co Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Assetmark Inc. Lowers Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
What’s the recovery path for long term holders of Bristol Myers Squibb Company Equity RightTrade Signal Summary & Technical Pattern Alert System - newser.com
Bristol-Myers Squibb Company (NYSE:BMY) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Bristol Myers Squibb Company stock hit record highs againExit Point & Entry Point Confirmation Signals - newser.com
Bristol Myers Squibb Co. Hits New 52-Week Low at $42.52 - Markets Mojo
Bristol Myers Squibb Company recovery potential after sell offWeekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Is Bristol Myers Squibb Company Celegne Contingent stock a fit for income portfolios2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Bristol-Myers Squibb Company (BMY.MX) stock price, news, quote and history - Yahoo! Finance UK
Bristol Myers Squibb (NYSE:BMY) Posts Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Bristol Myers Squibb Stock Hits Day High with 7.09% Surge - Markets Mojo
S&P 500 Falls 0.99% Amid 1,651 Advancing Stocks; Bristol Myers Soars 7.09% - Markets Mojo
Bristol-Myers Squibb Tops Forecasts But Leaves Questions Unanswered - Finimize
Germ Cell Tumors Market: Epidemiology, Therapies, Companies – DelveInsight | Featuring Takeda, Novartis, Bristol Myers Squibb, Merck & Co., Roche, and Bayer - Barchart.com
Retirement Systems of Alabama Has $60.37 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
New launches focus of latest financial prints at BMS, Merck & Co. - FirstWord Pharma
Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data - Insider Monkey
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings: Revenue Surpasse - GuruFocus
Bristol-Myers Squibb Shares Rally on Strong Quarterly Performance - AD HOC NEWS
Will Bristol Myers Squibb Company (BRM) stock beat growth indexesBuy Signal & Momentum Based Trading Signals - newser.com
Bristol-Myers Squibb Company (BMY) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Research Alert: CFRA Keeps Buy View On Shares Of Bristol-myers Squibb Company - 富途牛牛
Bristol-Myers Squibb Company (BMY) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Bristol-Myers Sets $160 Million Tax Reserve for Transfer Pricing - news.bloombergtax.com
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript Summary - 富途牛牛
Bladder Cancer MarketGlobal and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson - Yahoo Finance
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
Bristol rises on 2025 guidance raises, Q3 beats driven by Eliquis growth - MSN
Bristol Myers tries to temper anxiety over upcoming Cobenfy readout, unveils suite of PD-1xVEGF bispecific trials - Endpoints News
BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates - BioSpace
December 12th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View - TradingView
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock? - ts2.tech
Bristol Myers Squibb Outpaces Expectations With Strong New Drug Sales - Finimize
Bristol Myers beats quarterly revenue estimates on strong Opdivo sales - Reuters
Earnings call transcript: Bristol-Myers Squibb reports strong Q3 2025 earnings beat - Investing.com
Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewswire Inc.
Bristol Myers: Q3 Earnings Snapshot - News-Times
Bristol-Myers Squibb ups annual outlook as Q3 print exceeds estimates - Investing.com Nigeria
Bristol Myers Beats Quarterly Expectations on Drug Demand - Bloomberg.com
1.88%
0.81%
자본화:
|
볼륨(24시간):